Company
Temprian Therapeutics
Temprian Therapeutics is developing a novel, safe, and effective treatment for vitiligo.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Temprian Therapeutics is a spin-off from Northwestern University. The company's technology is based on over 25 years of research in the areas of gene therapies, autoimmune diseases and dermatology from the labs of Professor Caroline Le Poole.
Funding snapshot
- Total raised
- $275KSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $275K2019-01-25
Funding rounds
- Round, 2019
- $275K2019-01-25, SEC form D sold, 1 investor
Loading relationship preview